Cart
sales@molnova.com
Conduritol A
CAS No. 526-87-4
Conduritol A( —— )
Catalog No. M30987 CAS No. 526-87-4
Conduritol A has a hypoglycemic effect, can have an effect on regulating the metabolism of blood lipid, free-radical scavenging, enhancing the antioxidant ability, potentiating immune function; it also can markedly prevent the diabetic rats from getting cataracts through the inhibition of lens aldose reductase.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 556 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
Biological Information
-
Product NameConduritol A
-
NoteResearch use only, not for human use.
-
Brief DescriptionConduritol A has a hypoglycemic effect, can have an effect on regulating the metabolism of blood lipid, free-radical scavenging, enhancing the antioxidant ability, potentiating immune function; it also can markedly prevent the diabetic rats from getting cataracts through the inhibition of lens aldose reductase.
-
DescriptionConduritol A has a hypoglycemic effect, can have an effect on regulating the metabolism of blood lipid, free-radical scavenging, enhancing the antioxidant ability, potentiating immune function; it also can markedly prevent the diabetic rats from getting cataracts through the inhibition of lens aldose reductase.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number526-87-4
-
Formula Weight146.1
-
Molecular FormulaC6H10O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Zelminemab
Zelminemab (AMG-301) is a human monoclonal antibody designed to target and inhibit the PACAP type I (PAC1) receptor .
-
DPC AJ1951
Potent 14 amino acid peptide agonist of the parathyroid hormone (PTH) receptor (EC50 = 26 nM).
-
Parimifasor
Parimifasor(LYC-30937-EC, LYC30937) is an orally bioavailable, enteric-coated ATPase modulator as a gut-directed therapy for the treatment of inflammatory bowel disease (IBD).
